0001193125-26-182244.txt : 20260427 0001193125-26-182244.hdr.sgml : 20260427 20260427163752 ACCESSION NUMBER: 0001193125-26-182244 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harford Simon N.R. CENTRAL INDEX KEY: 0001443705 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901592 MAIL ADDRESS: STREET 1: AVON PRODUCTS, INC. STREET 2: 1345 AVENUE OF THE AMERICAS CITY: NEW YORK STATE: NY ZIP: 10105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001443705 Harford Simon N.R. false 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief Financial Officer false Common Stock 2026-04-27 4 D false 143595 14.5 D 0 D Stock Options (right to buy) 12.62 2026-04-27 4 D false 189043 D 2033-08-21 Common Stock 189043 0 D Stock Options (right to buy) 14.24 2026-04-27 4 D false 99073 D 2034-01-02 Common Stock 99073 0 D Stock Options (right to buy) 9.41 2026-04-27 4 D false 150517 D 2035-01-03 Common Stock 150517 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 108,478 shares of Common Stock and 35,117 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27